Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalo Therapeutics, Inc. (NASDAQ: AVTX) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other key documents. Avalo is a Delaware-incorporated clinical stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, and its filings offer structured insight into both its clinical progress and corporate actions.
Recent Form 8-K filings referenced by the company cover a range of material events. These include announcements of quarterly financial results, where Avalo reports information such as cash, cash equivalents and short-term investments and summarizes research and development and general and administrative expenses. Other 8-Ks describe the posting of updated investor presentations, which outline the development strategy for AVTX-009 and the design of the Phase 2 LOTUS trial in hidradenitis suppurativa (HS).
Additional 8-K reports detail governance and executive changes, such as the appointment of new directors and the hiring of senior executives like a Chief Business Officer. These filings summarize board decisions, committee assignments, equity awards, employment agreement terms and director compensation under Avalo’s non-employee director compensation plan. They also document director resignations and related amendments to outstanding equity awards.
For investors analyzing AVTX-009 and Avalo’s HS program, SEC filings complement press releases by providing formal descriptions of the LOTUS trial, including its randomized, double-blind, placebo-controlled Phase 2 design, dosing regimens and primary and secondary endpoints. They also link to exhibits such as press releases and investor presentations that expand on the company’s IL-1β scientific rationale.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools help summarize lengthy documents, highlight key sections on financial condition, clinical development updates, executive compensation and equity incentives, and make it easier to locate items such as Form 8-K exhibits and other relevant disclosures related to Avalo’s immune-mediated inflammatory disease programs.
Avalo Therapeutics, Inc. reported an equity transaction by its Chief Legal Officer on December 10, 2025. The officer reported a transaction in Avalo common stock coded “F” involving 1,016 shares at a price of $4.10 per share. After this transaction, the officer beneficially owns 3,634 shares of Avalo common stock. A note explains that these 3,634 shares were acquired under Avalo’s Employee Stock Purchase Plan as part of the reported transaction.
Avalo Therapeutics, Inc. chief financial officer Christopher Sullivan reported a change in his ownership of Avalo common stock. On 12/10/2025, 155 shares of common stock were disposed of at $4.1 per share, leaving him with beneficial ownership of 17,338 shares.
The beneficially owned amount includes 417 additional shares acquired pursuant to Avalo Therapeutics, Inc.'s Employee Stock Purchase Plan as a part of this reporting transaction. The report is a Form 4 filed by one reporting person in his capacity as an officer (chief financial officer).
Avalo Therapeutics, Inc. (AVTX) reported insider activity by one of its directors involving common stock and stock options on November 14, 2025. The director exercised a stock option to acquire 8,200 shares of common stock at an exercise price of $9.88 per share and then sold those 8,200 shares at a weighted average price of $14.3474 per share. On the same date, the director also sold an additional 3,167 shares of common stock at $14.30 per share, for total reported sales of 11,367 shares. Following these transactions, the director reported owning 0 shares of common stock directly and 16,400 stock options with an exercise price of $9.88 per share, expiring on August 13, 2034, which vest in three equal annual installments on March 28, 2025, 2026 and 2027.
Avalo Therapeutics (AVTX)1,300,000 shares of common stock for issuance under the Avalo Therapeutics, Inc. 2025 Inducement Award Plan. These shares may be issued and sold pursuant to awards granted under the plan.
The company identifies as a non-accelerated filer and a smaller reporting company. Standard indemnification and insurance provisions for directors and officers are described, and customary undertakings and incorporated reports are included.
Avalo Therapeutics (AVTX) reported Q3 2025 results with a net loss of
As of
The derivative liability was
Avalo Therapeutics (AVTX)Exhibit 99.1 under Item 2.02, stating it is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as specifically referenced.
The filing lists common stock trading on the Nasdaq Capital Market under AVTX and includes Inline XBRL cover pages as Exhibit 104.
Avalo Therapeutics reported a clinical milestone: it has completed enrollment in its Phase 2 LOTUS Trial evaluating AVTX-009 for hidradenitis suppurativa. The company disclosed the update via a press release furnished as Exhibit 99.1 to this report, dated October 29, 2025. This marks the transition from recruitment to data collection and analysis for the study.
Avalo Therapeutics, Inc. filed a current report to note that on October 10, 2025 it posted an updated investor presentation on its website. This presentation, attached as Exhibit 99.1, is intended for use from time to time in meetings with investors and is incorporated into the report by reference.
The filing does not describe new financial results or major transactions, but formally makes the investor presentation part of Avalo’s public disclosure record for shareholders and analysts who follow the company.
Avalo Therapeutics insider stock option grant to Chief Business Officer — Boyd Taylor received a stock option on The option covers 275,000 shares of common stock with an exercise price of
Boyd Taylor, identified as Chief Business Officer and a director, filed an initial Form 3 for Avalo Therapeutics, Inc. (AVTX) reporting the event date 10/01/2025. The filing states no securities are beneficially owned by the reporting person. The form was signed under power of attorney by Donald R. Reynolds on 10/06/2025. The submission confirms an initial disclosure with no ownership to report.
FAQ
What is the current stock price of Avalo Therapeutics (AVTX)?
What is the market cap of Avalo Therapeutics (AVTX)?
